Shares of United Therapeutics Corporation (NASDAQ:UTHR) have earned a consensus recommendation of “Hold” from the fifteen ratings firms that are presently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $130.22.

Several research firms recently weighed in on UTHR. Oppenheimer Holdings, Inc. restated a “buy” rating on shares of United Therapeutics Corporation in a research report on Monday, April 3rd. Cowen and Company restated a “hold” rating and issued a $121.00 price objective on shares of United Therapeutics Corporation in a research report on Wednesday, April 26th. Jefferies Group LLC cut shares of United Therapeutics Corporation from a “hold” rating to an “underperform” rating and reduced their price target for the company from $149.47 to $116.00 in a research report on Monday, March 6th. HC Wainwright reiterated a “hold” rating and set a $95.00 price target on shares of United Therapeutics Corporation in a research report on Monday, April 17th. Finally, Ladenburg Thalmann Financial Services cut shares of United Therapeutics Corporation from a “buy” rating to a “neutral” rating and set a $145.00 price target on the stock. in a research report on Thursday, February 23rd.

Shares of United Therapeutics Corporation (NASDAQ UTHR) opened at 129.92 on Friday. The company has a market capitalization of $5.85 billion, a price-to-earnings ratio of 9.12 and a beta of 1.56. The company’s 50 day moving average is $124.34 and its 200 day moving average is $138.37. United Therapeutics Corporation has a one year low of $97.52 and a one year high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, April 26th. The biotechnology company reported $3.89 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.12 by $0.77. The company had revenue of $370.50 million for the quarter, compared to analysts’ expectations of $399.59 million. United Therapeutics Corporation had a net margin of 41.04% and a return on equity of 34.74%. United Therapeutics Corporation’s revenue for the quarter was up .4% compared to the same quarter last year. During the same period in the prior year, the business earned $3.02 earnings per share. Equities research analysts predict that United Therapeutics Corporation will post $14.42 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/06/17/united-therapeutics-co-uthr-receives-130-22-average-price-target-from-brokerages-updated-updated-updated.html.

In other news, CEO Martine A. Rothblatt sold 1,219 shares of the firm’s stock in a transaction that occurred on Thursday, March 23rd. The shares were sold at an average price of $139.33, for a total value of $169,843.27. Following the transaction, the chief executive officer now owns 1,359 shares in the company, valued at $189,349.47. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 1,265 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $119.40, for a total transaction of $151,041.00. Following the completion of the transaction, the chief executive officer now owns 1,405 shares in the company, valued at approximately $167,757. The disclosure for this sale can be found here. Insiders sold 17,020 shares of company stock worth $2,154,373 in the last 90 days. Company insiders own 7.50% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the company. BlackRock Inc. raised its stake in shares of United Therapeutics Corporation by 4,222.8% in the first quarter. BlackRock Inc. now owns 4,741,985 shares of the biotechnology company’s stock worth $641,969,000 after buying an additional 4,632,287 shares during the last quarter. FMR LLC raised its stake in shares of United Therapeutics Corporation by 2.4% in the first quarter. FMR LLC now owns 4,138,779 shares of the biotechnology company’s stock worth $560,308,000 after buying an additional 98,529 shares during the last quarter. Scopia Capital Management LP acquired a new stake in shares of United Therapeutics Corporation during the third quarter worth approximately $483,266,000. Vanguard Group Inc. raised its stake in shares of United Therapeutics Corporation by 7.3% in the first quarter. Vanguard Group Inc. now owns 3,785,099 shares of the biotechnology company’s stock worth $512,427,000 after buying an additional 256,514 shares during the last quarter. Finally, State Street Corp raised its stake in shares of United Therapeutics Corporation by 7.6% in the first quarter. State Street Corp now owns 1,997,327 shares of the biotechnology company’s stock worth $270,411,000 after buying an additional 140,949 shares during the last quarter.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.